Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

M. Binder, S. V. Rajkumar, R. P. Ketterling, A. Dispenzieri, M. Q. Lacy, M. A. Gertz, F. K. Buadi, S. R. Hayman, Y. L. Hwa, S. R. Zeldenrust, J. A. Lust, S. J. Russell, N. Leung, P. Kapoor, R. S. Go, W. I. Gonsalves, R. A. Kyle, S. K. Kumar

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Cytogenetic evaluation at the time of diagnosis is essential for risk stratification in multiple myeloma, however little is known about the occurrence and prognostic significance of cytogenetic evolution during follow-up. We studied 989 patients with multiple myeloma, including 304 patients with at least two cytogenetic evaluations. Multivariable-adjusted regression models were used to assess the associations between the parameters of interest and cytogenetic evolution as well as overall survival. The prognostic significance of baseline cytogenetic abnormalities was most pronounced at the time of diagnosis and attenuated over time. In the patients with serial cytogenetic evaluations, the presence of t(11;14) at the time of diagnosis was associated with decreased odds of cytogenetic evolution during follow-up (odds ratio (OR)=0.22, 95% confidence interval (CI)=0.09-0.56, P=0.001), while the presence of at least one trisomy or tetrasomy was associated with increased odds (OR=2.96, 95% CI=1.37-6.42, P=0.006). The development of additional abnormalities during the 3 years following diagnosis was associated with increased subsequent mortality (hazard ratio=3.31, 95% CI=1.73-6.30, P<0.001). These findings emphasize the importance of the underlying clonal disease process for risk assessment and suggest that selected patients may benefit from repeated risk stratification.

Original languageEnglish (US)
Article numbere401
JournalBlood cancer journal
StatePublished - Mar 11 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this